← 30 October 2026's Current Affairs · Science & Tech GA Prelims ★★★★☆ Mains ★★☆☆☆
India rejects patent claim on BPaL drug regimen
Why in News?
A patent refused on a TB regimen: the Section 3(d) evergreening test GS2 Health and IPR answers need
Patent Office rejects TB Alliance's BPaL application; generics may benefit.
Why it matters: factual, Prelims-type
What you need to know
2 min read
On 27 October 2026 the Indian Patent Office rejected a patent application by the US-based TB Alliance for BPaL, a drug combination for drug-resistant tuberculosis.
The decision could open the door to generic competition, though its effect on treatment costs will depend on availability, pricing and access to care.
Sources: Topper IAS editorial (PIB / The Hindu / Indian Express)
Key facts
Remember these
- On 27 October 2026 the Indian Patent Office rejected TB Alliance's patent application for BPaL.
- BPaL is a combination regimen for drug-resistant tuberculosis; TB Alliance is a US-based product development non-profit.
- Rejection may allow Indian generic manufacturers to produce the regimen, though costs depend on availability, pricing and access to care.
- Section 3(d) of the Patents Act, 1970 bars patents on new forms of known substances without enhanced efficacy.
- India's patent law operates under the TRIPS-compliant 2005 amendment, with Patent Office decisions appealable.
Prelims · Mains
How the exam will ask it
Prelims
- Section 3(d) of the Indian Patents Act, 1970 prevents patenting of mere new forms of a known substance unless there is significant enhancement of known efficacy.
- The Indian Patent Office functions under the Controller General of Patents, Designs and Trade Marks.
- A patent rejection can open the way for generic competition, whereas a granted patent gives the holder exclusive rights, generally for 20 years.
- BPaL is a regimen used against drug-resistant tuberculosis, not malaria or leprosy.
Mains
GS2 (Health) and GS3 (IPR): India's patent refusal on a drug-resistant TB regimen highlights the balance between innovation incentives and public health access. The Patents Act, 1970 safeguards such as Section 3(d), together with TRIPS flexibilities, shape what can be patented, while the effect on affordability depends on generic supply and access to care. The way forward is to pair transparent patent scrutiny with procurement, local manufacturing and strong delivery under the National TB Elimination Programme.
Quick recall
Answer before you reveal
On 27 October 2026 the Indian Patent Office rejected a patent application by the TB Alliance for BPaL, a drug combination used against:
- Drug-resistant malaria
- Drug-resistant tuberculosis
- Multidrug-resistant typhoid
- Drug-resistant leprosy
Show answer
Answer: B — Correct: Drug-resistant tuberculosis — BPaL is a shorter regimen for drug-resistant TB; rejecting the claim may allow generic makers to supply it. • Drug-resistant malaria — wrong: BPaL is a TB regimen; malaria is treated with artemisinin-based combinations. • Multidrug-resistant typhoid — wrong: Typhoid is bacterial but not the target of the BPaL regimen, which is for TB. • Drug-resistant leprosy — wrong: Leprosy is treated with multidrug therapy; BPaL is a tuberculosis regimen.
Convert this topic into marks
Today's 10-MCQ test · instant analysis · Powered by AdaptIQ